![conference banner](/images/conference-banner.jpeg)
Abstract
Over the past 5 years, the adenosine A2A receptor (A2AR) is emerging as an attractive therapeutic target for modulating brain injury in a variety of animal models of neurological disorders including stroke. The evidence we have to date indicates that both adenosine and A2A antagonists are neuroprotective in ischaemic brain injury. From drug development perspective, administering A2A antagonists in association with inhibitors of adenosine kinase may represent a novel strategy for treating stroke. Despite the well-documented neuroprotection by A2AR antagonists, the mechanism by which A2ARs affect brain injury remains largely unknown. In this section, we also summarize the experimental evidence for A2AR modulation of glial function as possible contribution to the modulation of brain injury. In vitro and in vivo studies reveal that in response to local neuroinflammation following brain insults, time-dependent, inflammatory signal-mediated induction of the A2AR in glial cells (particularly microglial cells) make this cell type particularly sensitive to A2AR modulation of brain injury. Furthermore, in contrast to the generally held view that the A2AR exerts predominantly anti-inflammatory effects (based upon studies in peripheral organs), the A2AR modulation of neuroinflammation may differentially affect the outcome of brain injury, depending on the nature of brain insults. Thus, in association with their ability to reduce brain injury, inactivation of the A2AR in most models and activation of A2AR in some cases have been shown to attenuate brain inflammation through control of the proliferation and production of proinflammatory cytokines,
Keywords: Adenosine, adenosine A2A receptor, neuroprotection, ischemia, neuroinflammation, excitoxicity, microglia, astrocytes, bone marrow derived cells
Current Pharmaceutical Design
Title: Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Volume: 14 Issue: 15
Author(s): Jiang-Fan Chen and Felicita Pedata
Affiliation:
Keywords: Adenosine, adenosine A2A receptor, neuroprotection, ischemia, neuroinflammation, excitoxicity, microglia, astrocytes, bone marrow derived cells
Abstract: Over the past 5 years, the adenosine A2A receptor (A2AR) is emerging as an attractive therapeutic target for modulating brain injury in a variety of animal models of neurological disorders including stroke. The evidence we have to date indicates that both adenosine and A2A antagonists are neuroprotective in ischaemic brain injury. From drug development perspective, administering A2A antagonists in association with inhibitors of adenosine kinase may represent a novel strategy for treating stroke. Despite the well-documented neuroprotection by A2AR antagonists, the mechanism by which A2ARs affect brain injury remains largely unknown. In this section, we also summarize the experimental evidence for A2AR modulation of glial function as possible contribution to the modulation of brain injury. In vitro and in vivo studies reveal that in response to local neuroinflammation following brain insults, time-dependent, inflammatory signal-mediated induction of the A2AR in glial cells (particularly microglial cells) make this cell type particularly sensitive to A2AR modulation of brain injury. Furthermore, in contrast to the generally held view that the A2AR exerts predominantly anti-inflammatory effects (based upon studies in peripheral organs), the A2AR modulation of neuroinflammation may differentially affect the outcome of brain injury, depending on the nature of brain insults. Thus, in association with their ability to reduce brain injury, inactivation of the A2AR in most models and activation of A2AR in some cases have been shown to attenuate brain inflammation through control of the proliferation and production of proinflammatory cytokines,
Export Options
About this article
Cite this article as:
Chen Jiang-Fan and Pedata Felicita, Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors, Current Pharmaceutical Design 2008; 14 (15) . https://dx.doi.org/10.2174/138161208784480126
DOI https://dx.doi.org/10.2174/138161208784480126 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Creatine and the Liver: Metabolism and Possible Interactions
Mini-Reviews in Medicinal Chemistry Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology <i>In Silico</i> Study of 1, 4 Alpha Glucan Branching Enzyme and Substrate Docking Studies
Current Proteomics Development of Health Products from Natural Sources
Current Medicinal Chemistry Green Tea (Camellia sinensis) Protects Against Arsenic Neurotoxicity via Antioxidative Mechanism and Activation of Superoxide Dismutase Activity
Central Nervous System Agents in Medicinal Chemistry Medical Applications of Collagen and Collagen-Based Materials
Current Medicinal Chemistry GPCR Drug Discovery: Novel Ligands for CNS Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Inflammation: Beneficial or Detrimental After Spinal Cord Injury?
Recent Patents on CNS Drug Discovery (Discontinued) NPY Family of Hormones: Clinical Relevance and Potential Use in Gastrointestinal Disease
Current Topics in Medicinal Chemistry Pharmacogenetic Variation and Metformin Response
Current Drug Metabolism Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition
Current Medicinal Chemistry Epidemiology of Traumatic Brain Injury in Abu-Dhabi, UAE
New Emirates Medical Journal Pharmacology and Toxicology of Cannabis Derivatives and Endocannabinoid Agonists
Recent Patents on CNS Drug Discovery (Discontinued) Prevalence of Bruxism in Children and Adolescents with Cerebral Palsy: Systematic Review and Meta-analysis
Current Pediatric Reviews Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals The Role of Melatonin in Pancreatic Protection: Could Melatonin be Used in the Treatment of Acute Pancreatitis?
Current Pharmaceutical Design Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology General Anesthetics in Brain Injury: Friends or Foes?
Current Pharmaceutical Design The Mechanisms of Gastric Mucosal Injury: Focus on Microvascular Endothelium as a Key Target
Current Medicinal Chemistry Pro-inflammatory Cytokines in Animal and Human Gestation
Current Pharmaceutical Design